1. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis 
Laura E. Targownik, Aruni Tennakoon, Stella Leung, Lisa M. Lix, Harminder Singh, Charles N. Bernstein 
Clinical Gastroenterology and Hepatology 
Volume 15, Issue 7, Pages e1 (July 2017)
DOI: /j.cgh
Copyright © 2017 AGA Institute Terms and Conditions

2. Figure 1 Point prevalence of anti-TNF use by calendar date.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

3. Figure 2 Cumulative prevalence of anti-TNF use by calendar date.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

4. Figure 3
Time between initial diagnosis of IBD and initial receipt of anti-TNF.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

5. Figure 4
Time until initial receipt of anti-TNF from first IM dispensation or first instance of corticosteroid dependence, by era of diagnosis.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

6. Figure 5
Comparison of individual cumulative corticosteroid dosing between eras, matched on time from diagnosis until anti-TNF use.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

7. Supplementary Figure 1
Time from disease onset to time to first anti-TNF, by severity of disease in first year after diagnosis.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions